Education
About Us
Working with TipRanks
Follow Us
Nyxoah (NYXH)
NASDAQ:NYXH
NYXH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.76 - $12.79
Previous CloseN/A
Volume100.61K
Average Volume (3M)76.38K
Market Cap
$207.35M
Enterprise Value$242.88M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)0.00
Price to Earnings (P/E)―
Beta1.30
Next Earnings
May 13, 2025EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.95
Shares Outstanding34,386,765
10 Day Avg. Volume141,058
30 Day Avg. Volume76,377
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)82.28
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$14.98Price Target Upside146.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Nyxoah News
PremiumCompany Announcements
Nyxoah Nears FDA Approval for Genio System---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyGenio system resulted in a clinically meaningful 71.0% median reduction in Apnea Hypopnea Index (AHI) while sleeping supine at 12 months compared with baseline.
Financial HealthNyxoah reported a proforma cash position of €95.6M, indicating strong financial health.
Market ExpansionPotential U.S. approval of Genio in 1Q25 could significantly expand Nyxoah's market reach and revenue opportunities.
Bears Say
European Market ChallengesThe European market will continue to be difficult to grow and penetrate, posing a challenge for Nyxoah's expansion efforts in that region.
Regulatory DelaysThere is a delay in the Belgium facility inspection, which is expected to push US approval to the first quarter of 2025.
Underperformance4Q24 Genio sales were below estimates, with reported sales of €1.3M compared to an expected €2.4M.
---
Ownership Overview
11.80%
Insiders
5.54% Mutual Funds
9.10% Other Institutional Investors
73.53% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
NYXH FAQ
What was Nyxoah’s price range in the past 12 months?
Nyxoah lowest stock price was $5.76 and its highest was $12.79 in the past 12 months.
What is Nyxoah’s market cap?
Nyxoah’s market cap is $207.35M.
When is Nyxoah’s upcoming earnings report date?
Nyxoah’s upcoming earnings report date is May 13, 2025 which is in 35 days.
How were Nyxoah’s earnings last quarter?
Nyxoah released its earnings results on Mar 13, 2025. The company reported -$0.508 earnings per share for the quarter, beating the consensus estimate of -$0.513 by $0.005.
Is Nyxoah overvalued?
According to Wall Street analysts Nyxoah’s price is currently Undervalued.
Does Nyxoah pay dividends?
Nyxoah does not currently pay dividends.
What is Nyxoah’s EPS estimate?
Nyxoah’s EPS estimate is -0.52.
How many shares outstanding does Nyxoah have?
Nyxoah has 34,386,765 shares outstanding.
What happened to Nyxoah’s price movement after its last earnings report?
Nyxoah reported an EPS of -$0.508 in its last earnings report, beating expectations of -$0.513. Following the earnings report the stock price went up 3.289%.
Which hedge fund is a major shareholder of Nyxoah?
Currently, no hedge funds are holding shares in NYXH
---
Nyxoah Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.98 (146.38% Upside)
$14.98 (146.38% Upside)
Blogger Sentiment
Bullish
NYXH Sentiment 70%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 253.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-50.24%
12-Months-Change
Fundamentals
Return on Equity
-56.71%
Trailing 12-Months
Asset Growth
19.60%
Trailing 12-Months
Company Description
Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
---
NYXH Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements in clinical efficacy, U.S. market readiness, and international expansion. However, increased operating losses and changes in revenue recognition that impact short-term financial performance were noted. The company's strong cash position supports its strategic initiatives.Read More>---
NYXH Stock 12 Month Forecast
Average Price Target
$14.98
▲(146.38% Upside)
Technical Analysis
Irhythm Technologies
―
Inspire Medical Systems
―
Senseonics Holdings
―
Stereotaxis
―
NovoCure
―
Smith & Nephew Snats
―
Best Analysts Covering NYXH
1 Year
1 Year Success Rate
7/16 ratings generated profit
1 Year Average Return
-0.21%
assigned a buy rating 8 months ago
Copying Adam Maeder's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of -0.21% per trade.
---